SBIR Phase I: Tunable Oxygenating Biopolymer Hydrogel Dressings for Chronic Wound Care

SBIR 第一阶段：用于慢性伤口护理的可调节氧化生物聚合物水凝胶敷料

• 批准号: 1647555
• 负责人: Andreas Inmann
• 金额: $ 22.5万
• 依托单位: O2 RegenTech LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-12-15 至 2018-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1647555&HistoricalAwards=false
• 关键词: SBIR; Phase; Tunable; Oxygenating; Biopolymer

This Small Business Innovation Research (SBIR) Phase I project will investigate novelapproaches for biopolymer materials that uniquely enable oxygen incorporation into hydrogeldressings to improve and accelerate chronic wound healing. The proposed work differs drasticallyfrom other research programs and commercial efforts to use oxygen in chronic wound healing asit is the first to combine oxygen, a moist and clean healing environment, and antimicrobialproperties into one cost-effective and easy-to-use product. Current commercial oxygen-deliverytherapies for wound care, e.g., hyperbaric oxygen chambers and topical oxygen devices, areintermittent, inconvenient to use, and require access to expensive specialized equipment.Successfully introducing oxygenating wound dressings to the market will allow addressing theserious and pervasive burden on healthcare facilities and the exorbitant costs associated withchronic wound care. In the USA alone, diabetic chronic wounds cause direct healthcare-relatedcosts of $1.5 billion and total direct and indirect costs of $20 billion.The proposed research incorporates proprietary patent-pending biopolymer materials andprocessing methods to create oxygenating hydrogels that can be made into wound dressings.The dressings have the unique potential to provide uniform and tunable oxygenation to healchronic wounds. Dressing embodiments, syntheses, and manufacturing techniques will beexplored to improve product performance and characteristics, reduce costs, and demonstratecommercial feasibility and viability of the production process. Thus, knowledge of biomaterials forwound care will be significantly advanced by the proposed research. Prototype wound dressingswill be characterized and tested based on customer requirements.

这项小型企业创新研究（SBIR）I阶段项目将研究生物聚合物材料的新颖性，这些小型聚合物材料唯一地将氧气掺入氢糖层中，以改善和加速慢性伤口愈合。拟议的工作与其他研究计划和商业努力在慢性伤口愈合中使用氧气截然不同，这是第一个结合氧​​气，潮湿，清洁的愈合环境以及抗菌质培养物，成为一种具有成本效益且易于使用的产品。当前用于伤口护理的商用氧气递送治疗，例如，高压氧室和局部氧气设备，是间隔，不便的使用，并需要使用昂贵的专用设备。成功地将氧合的伤口敷料引入市场上，可以解决这种造成的伤口，以解决这些机构的机构，并与医疗服务相关联。仅在美国，糖尿病性慢性伤口导致直接医疗保健相关的镜头为15亿美元，直接和间接成本为200亿美元。拟议的研究结合了专有专利待发的生物聚合物材料和处理方法，可制造氧化的水凝胶，从而使敷料具有良好的伤口，从而使越野敷料具有独特的伤口。敷料实施例，合成和制造技术将进行探索，以提高产品性能和特征，降低成本以及演示商业的可行性和生产过程的可行性。因此，拟议的研究将显着提高生物材料的知识。原型伤口敷料将根据客户需求进行特征和测试。